



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

January 27, 2005

Docket No. 03003167
Control No. 136187

License No. 37-12771-01

John Massimilla
Vice President, Administration
The Chambersburg Hospital
112 North 7th Street
P.O. Box 6005
Chambersburg, PA 17201-6005

SUBJECT: THE CHAMBERSBURG HOSPITAL, ISSUANCE OF LICENSE AMENDMENT,
CONTROL NO. 136187

Dear Mr. Massimilla:

This refers to your license amendment request. Enclosed with this letter is the amended license. The long-term waste storage closet may be released for unrestricted use.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Please note that on October 25, 2004, the NRC suspended public access to ADAMS, and initiated an additional security review of publicly available documents to ensure that potentially sensitive information is removed from the ADAMS database accessible through the NRC's web site. Interested members of the public may obtain copies of the referenced documents for review and/or copying by contacting the NRC Public Document Room pending resumption of public access to ADAMS. The NRC Public Document Room is located at NRC Headquarters in Rockville, MD, and can be contacted at 800-397-4209 or 301-415-4737 or pdr@nrc.gov.

Thank you for your cooperation.

Sincerely,

Original signed by Tara L. Weidner

Tara L. Weidner
Health Physicist
Medical Branch
Division of Nuclear Materials Safety

Enclosure:

J. Massimilla
The Chambersburg Hospital

2

Amendment No. 49

cc:
David R. Brill, M.D., Radiation Safety Officer

J. Massimilla
The Chambersburg Hospital

3

DOCUMENT NAME: E:\Filenet\ML050350168.wpd

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI		DNMS/RI			
NAME	TWeidner /TLW/							
DATE	1/27/05							

OFFICIAL RECORD COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated December 15, 2004, 3. License number 37-12771-01 is amended in its entirety to read as follows:
1. The Chambersburg Hospital 112 North Seventh Street	
2. Chambersburg, Pennsylvania 17201-6005	4. Expiration date January 31, 2006 5. Docket No. 030-03167 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 500 millicuries
D. Palladium 103	D. Sealed sources (Best Medical International Model 2335)	D. 400 millicuries
E. Iodine 125	E. Sealed sources (Mills Biopharmaceuticals Model I-125-SL)	E. 200 millicuries
F. Gadolinium 153	F. Sealed Sources (North American Scientific, Inc. Model 3601 or DuPont Merck Model NES-8412)	F. 300 millicuries per source and 800 millicuries total

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
37-12771-01Docket or Reference Number
030-03167

Amendment No. 49

- D. and E. Any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.
- F. For use in an ADAC Laboratories Model Vantage device for patient attenuation correction during S.P.E.C.T. imaging.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 112 North Seventh Street, Chambersburg, Pennsylvania and Summit Health Center, 757 Norland Avenue, Suite 102, Chambersburg, Pennsylvania.
11. The Radiation Safety Officer for this license is David Brill, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized Users**Material and Use**

Peter J.W. Fang, M.D.

35.100; 35.200; Gadolinium 153 for patient attenuation during S.P.E.C.T. imaging

Henry Ta-Mah Ching, M.D.

35.100; 35.200; Gadolinium 153 for patient attenuation during S.P.E.C.T. imaging

Ann E. Lewandowski, M.D.

35.100; 35.200; 35.300; Gadolinium 153 for patient attenuation during S.P.E.C.T. imaging

Robert S. Pyatt, M.D.

35.100; 35.200; 35.300; Gadolinium 153 for patient attenuation during S.P.E.C.T. imaging

Philip J. Sabri, M.D.

35.100; 35.200; 35.300; Gadolinium 153 for patient attenuation during S.P.E.C.T. imaging

Thane Toe Thane, M.D.

35.100; 35.200; 35.300; Gadolinium 153 for patient attenuation during S.P.E.C.T. imaging

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
37-12771-01Docket or Reference Number
030-03167

Amendment No. 49

Authorized Users

Frank Louis D'Amelio, M.D.

Michael Edward Shivers, M.D.

Kevin Michael Cregan, M.D.

David R. Brill, M.D.

Niteen N. Sukerkar, M.D.

Julia Blum, M. D.

Material and Use35.100; 35.200; 35.300; Gadolinium 153 for
patient attenuation during S.P.E.C.T. imaging

35.100; 35.200

35.100; 35.200

35.100; 35.200; 35.300

35.100; 35.200; 35.300; Gadolinium 153 for
patient attenuation during S.P.E.C.T. imagingPalladium 103 and Iodine 125 for uses
permitted by 35.400

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
37-12771-01Docket or Reference Number
030-03167

Amendment No. 49

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated January 31, 1995
- B. Letter dated June 13, 1995
- C. Letter dated December 12, 1995
- D. Letter dated July 29, 1999
- E. Letter dated September 3, 1999
- F. Letter dated March 11, 2002, except the Brachytherapy QMP (ML020790184)
- G. Letter dated June 17, 2003 (ML031840314)
- H. Letter dated July 16, 2004 (ML042150422)
- I. Letter dated December 15, 2004 (ML050140338)

For the U.S. Nuclear Regulatory Commission

Date January 27, 2005
bbbbbbbbbbbbbbbbbbbbbbbbbb

Original signed by Tara L. Weidner

By _____
Tara L. Weidner
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406